Active Ingredient History

  • Now
Tavaborole is a boron-based pharmaceutical agent indicated for the topical treatment of toenail onychomycosis, a fungal infection of the nail and nail bed due to Trichophyton rubrum or Trichophyton mentagrophytes infection. Tavaborole acts by inhibiting an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS) - Leucyl-tRNA synthetase. Leucyl-tRNA synthetase is an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu). Tavaborole’s low molecular weight (approximately half of most antifungals, such as terbinafine and efinaconazole) permits optimal nail plate penetration, superior to that of existing topical antifungal medications.   NCATS

  • Mol. Mass: 151.931
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$145.0342 - $1071.6100
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole | 5-fluoro-2,1-benzoxaborol-1(3h)-ol | an2690 | an 2690 | an-2690 | kerydin | tavaborole


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue